The future is female

Houston nonprofit launches accelerator program to give women-led startup a leg up within health care

Ignite Healthcare Network has hosted a pitch compeition for a few years now, but this is the first year for its mini-accelerator program. Courtesy of Ignite

Within health care, female consumers make 80 percent of the buying power while women hold 65 percent of the workforce's jobs, according to a recent study. However, when you look at the C-suites in the industry, those percentages fall drastically, says Ayse McCracken.

"For as many women as there are involved in health care, it's not reflected in leadership," says McCracken, founder of Ignite Healthcare Network. "That's what brought us together."

Just 30 percent of health care C-suites are women — and only 13 percent have female CEOs, per the report by Oliver Wyman. Houston-based nonprofit Ignite is an organization comprised of over 150 of these rare female health care execs and focused on clearing a path for future female leaders in the industry.

McCracken founded the network in 2016, and her team established a "Shark Tank-style" pitch competition. After three years of the annual event seeing successes, Ignite is introducing its inaugural mini-accelerator program.

"As we saw this innovation economy and startup space begin to evolve in the city, it seemed that our contribution to this was that we could help incubate and find companies that had high likelihood of success," says McCracken.

Ignite and its partners identified 13 female-led companies from all around the world were selected from over 80 applications and now will go through a 10-week program called the Customer-Partner Program. Each company is paired with a partner and potential customer — from Memorial Hermann and Texas Children's Hospital to Humana and Gallagher.

Here are the participating female-led startups:

  • iTreatMD from San Francisco
  • BabyNoggin (by Qidza) from San Francisco
  • Ria Health from San Francisco
  • Savonix from San Francisco
  • MotiSpark from Los Angeles
  • UpHold Health from Chicago
  • Sound Scouts from Sydney, Australia
  • Augment Therapy from Cleveland, Ohio
  • Oncora Medical Philadelphia
  • Materna Medical from Mountain View, California
  • Path Ex Inc Houston
  • PyrAmes Inc. from Cupertino, California
  • Spoke Health Denver

The Fire Pitch Competition will take place on October 17 at the Texas Medical Center's Innovation Institute. Hundreds of thousands of dollars in prizes is on the line for the 13 companies.

"This year's event is already receiving increased recognition from investors," says Ignite board member and event co-chair, Cheryl Stavins, in a release. "In addition to the top three finalists sharing awards that include entry into the TMCx Digital Health Accelerator, over $125,000 in professional services, and cash prizes of $10,000, Fire Pitch participants will be eligible for investment prizes."

The Texas Halo Fund will be awarding its $100,000 investment prize, called the Corona Award, along with a $50,000 prize from TMC Innovation Institute.

Beyond the new program, McCracken says she wants to expand Ignite's reach and capabilities for its members and startups — including new investment opportunities.

"I think what we're doing now is reaching out beyond Houston and looking at how we can continue to grow the opportunity to have an impact and help women-led companies and women in organizations," she says.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted